<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet href="http://www.blogger.com/styles/atom.css" type="text/css"?><feed xmlns='http://www.w3.org/2005/Atom' xmlns:openSearch='http://a9.com/-/spec/opensearchrss/1.0/' xmlns:blogger='http://schemas.google.com/blogger/2008' xmlns:georss='http://www.georss.org/georss' xmlns:gd="http://schemas.google.com/g/2005" xmlns:thr='http://purl.org/syndication/thread/1.0'><id>tag:blogger.com,1999:blog-6740498378870516287</id><updated>2024-11-26T11:23:29.508-08:00</updated><title type='text'>Blog da Farmacêutica</title><subtitle type='html'></subtitle><link rel='http://schemas.google.com/g/2005#feed' type='application/atom+xml' href='http://helgabischoff.blogspot.com/feeds/posts/default'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default?redirect=false'/><link rel='alternate' type='text/html' href='http://helgabischoff.blogspot.com/'/><link rel='hub' href='http://pubsubhubbub.appspot.com/'/><author><name>Helga Bischoff</name><uri>http://www.blogger.com/profile/08405263765684348837</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEihKVWoB58uUoLc7y6Qb9tkzXpeTsY_XFfn0-AufGMvESm9uBmZ5fzFANu4dshHkqmWyE9f0TmESGfuDsgaeSD0gOHMMnmm97FLV3i1B5Hl9lTpw7kQvqbn4G4-s6OJlfo/s220/foto+nova.png'/></author><generator version='7.00' uri='http://www.blogger.com'>Blogger</generator><openSearch:totalResults>25</openSearch:totalResults><openSearch:startIndex>1</openSearch:startIndex><openSearch:itemsPerPage>25</openSearch:itemsPerPage><entry><id>tag:blogger.com,1999:blog-6740498378870516287.post-7393264441711584182</id><published>2012-11-05T15:15:00.000-08:00</published><updated>2012-11-05T15:15:03.038-08:00</updated><title type='text'>Farmacêutica é a melhor e mais valorizada profissão nos Estados Unidos </title><content type='html'>Uma farmacêutica ganha o equivalente a R$ 16.000,00 / mês nos Estados Unidos, bem diferente da realidade do Brasil.... será que algum dia chegaremos lá?&lt;br /&gt;
&lt;a href=&quot;http://www.forbes.com/sites/jennagoudreau/2012/07/16/the-20-best-paying-jobs-for-women-in-2012/&quot;&gt;http://www.forbes.com/sites/jennagoudreau/2012/07/16/the-20-best-paying-jobs-for-women-in-2012/&lt;/a&gt;&lt;br /&gt;
&lt;br /&gt;</content><link rel='replies' type='application/atom+xml' href='http://helgabischoff.blogspot.com/feeds/7393264441711584182/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://helgabischoff.blogspot.com/2012/11/farmaceutica-e-melhor-e-mais-valorizada.html#comment-form' title='1 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/7393264441711584182'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/7393264441711584182'/><link rel='alternate' type='text/html' href='http://helgabischoff.blogspot.com/2012/11/farmaceutica-e-melhor-e-mais-valorizada.html' title='Farmacêutica é a melhor e mais valorizada profissão nos Estados Unidos '/><author><name>Helga Bischoff</name><uri>http://www.blogger.com/profile/08405263765684348837</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEihKVWoB58uUoLc7y6Qb9tkzXpeTsY_XFfn0-AufGMvESm9uBmZ5fzFANu4dshHkqmWyE9f0TmESGfuDsgaeSD0gOHMMnmm97FLV3i1B5Hl9lTpw7kQvqbn4G4-s6OJlfo/s220/foto+nova.png'/></author><thr:total>1</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6740498378870516287.post-7461760176485770685</id><published>2012-06-30T17:19:00.001-07:00</published><updated>2012-06-30T17:19:52.039-07:00</updated><title type='text'></title><content type='html'>&lt;div style=&quot;color: blue; font-family: Arial,Helvetica,sans-serif; text-align: justify;&quot;&gt;
&lt;b&gt;Muitos medicamentos podem ser administrados via hipodermóclise, apesar de não constar esta indicação em bula. Abaixo segue tabela com alguns dos medicamentos mais utilizados em cuidados paliativos que podem ou não ser administrados via hipodermóclise.&lt;/b&gt;&lt;/div&gt;
&lt;div style=&quot;text-align: center;&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div style=&quot;text-align: center;&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div style=&quot;text-align: center;&quot;&gt;

 &lt;/div&gt;
&lt;table border=&quot;0&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;width: 401px;&quot;&gt;&lt;colgroup&gt;&lt;col style=&quot;mso-width-alt: 4736; mso-width-source: userset; width: 111pt;&quot; width=&quot;148&quot;&gt;&lt;/col&gt;
 &lt;col style=&quot;mso-width-alt: 8096; mso-width-source: userset; width: 190pt;&quot; width=&quot;253&quot;&gt;&lt;/col&gt;
 &lt;/colgroup&gt;&lt;tbody&gt;
&lt;tr height=&quot;25&quot; style=&quot;height: 18.75pt;&quot;&gt;
  &lt;td class=&quot;xl66&quot; height=&quot;25&quot; style=&quot;background: black; border: .5pt solid windowtext; color: white; font-family: Corbel; font-size: 14.0pt; font-weight: 700; height: 18.75pt; mso-pattern: black none; text-decoration: none; text-line-through: none; text-underline-style: none; width: 111pt;&quot; width=&quot;148&quot;&gt;Medicamentos&lt;/td&gt;
  &lt;td class=&quot;xl67&quot; style=&quot;background: black; border-left: none; border: .5pt solid windowtext; color: white; font-family: Corbel; font-size: 14.0pt; font-weight: 700; mso-pattern: black none; text-decoration: none; text-line-through: none; text-underline-style: none; width: 190pt;&quot; width=&quot;253&quot;&gt;Pode ser adm. por via SC?&lt;/td&gt;
 &lt;/tr&gt;
&lt;tr height=&quot;20&quot; style=&quot;height: 15.0pt;&quot;&gt;
  &lt;td class=&quot;xl68&quot; height=&quot;20&quot; style=&quot;border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; height: 15.0pt; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Alfentanila&lt;/td&gt;
  &lt;td class=&quot;xl69&quot; style=&quot;border-left: none; border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Sim&lt;/td&gt;
 &lt;/tr&gt;
&lt;tr height=&quot;20&quot; style=&quot;height: 15.0pt;&quot;&gt;
  &lt;td class=&quot;xl68&quot; height=&quot;20&quot; style=&quot;border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; height: 15.0pt; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Ampicilina&lt;/td&gt;
  &lt;td class=&quot;xl69&quot; style=&quot;border-left: none; border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Sim&lt;/td&gt;
 &lt;/tr&gt;
&lt;tr height=&quot;20&quot; style=&quot;height: 15.0pt;&quot;&gt;
  &lt;td class=&quot;xl68&quot; height=&quot;20&quot; style=&quot;border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; height: 15.0pt; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Atropina&lt;/td&gt;
  &lt;td class=&quot;xl69&quot; style=&quot;border-left: none; border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Sim&lt;/td&gt;
 &lt;/tr&gt;
&lt;tr height=&quot;20&quot; style=&quot;height: 15.0pt;&quot;&gt;
  &lt;td class=&quot;xl68&quot; height=&quot;20&quot; style=&quot;border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; height: 15.0pt; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Bupivacaína&lt;/td&gt;
  &lt;td class=&quot;xl69&quot; style=&quot;border-left: none; border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Sim&lt;/td&gt;
 &lt;/tr&gt;
&lt;tr height=&quot;20&quot; style=&quot;height: 15.0pt;&quot;&gt;
  &lt;td class=&quot;xl68&quot; height=&quot;20&quot; style=&quot;border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; height: 15.0pt; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Cefepima&lt;/td&gt;
  &lt;td class=&quot;xl69&quot; style=&quot;border-left: none; border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Sim&lt;/td&gt;
 &lt;/tr&gt;
&lt;tr height=&quot;20&quot; style=&quot;height: 15.0pt;&quot;&gt;
  &lt;td class=&quot;xl68&quot; height=&quot;20&quot; style=&quot;border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; height: 15.0pt; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Cefotaxima&lt;/td&gt;
  &lt;td class=&quot;xl69&quot; style=&quot;border-left: none; border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Não
  há referências&lt;/td&gt;
 &lt;/tr&gt;
&lt;tr height=&quot;20&quot; style=&quot;height: 15.0pt;&quot;&gt;
  &lt;td class=&quot;xl68&quot; height=&quot;20&quot; style=&quot;border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; height: 15.0pt; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Ceftazidima&lt;/td&gt;
  &lt;td class=&quot;xl69&quot; style=&quot;border-left: none; border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Não
  há referências&lt;/td&gt;
 &lt;/tr&gt;
&lt;tr height=&quot;20&quot; style=&quot;height: 15.0pt;&quot;&gt;
  &lt;td class=&quot;xl68&quot; height=&quot;20&quot; style=&quot;border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; height: 15.0pt; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Ceftriaxona&lt;/td&gt;
  &lt;td class=&quot;xl69&quot; style=&quot;border-left: none; border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Sim&lt;/td&gt;
 &lt;/tr&gt;
&lt;tr height=&quot;20&quot; style=&quot;height: 15.0pt;&quot;&gt;
  &lt;td class=&quot;xl68&quot; height=&quot;20&quot; style=&quot;border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; height: 15.0pt; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Cetamina&lt;/td&gt;
  &lt;td class=&quot;xl69&quot; style=&quot;border-left: none; border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Sim&lt;/td&gt;
 &lt;/tr&gt;
&lt;tr height=&quot;20&quot; style=&quot;height: 15.0pt;&quot;&gt;
  &lt;td class=&quot;xl68&quot; height=&quot;20&quot; style=&quot;border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; height: 15.0pt; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Cetorolaco&lt;/td&gt;
  &lt;td class=&quot;xl69&quot; style=&quot;border-left: none; border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Sim&lt;/td&gt;
 &lt;/tr&gt;
&lt;tr height=&quot;20&quot; style=&quot;height: 15.0pt;&quot;&gt;
  &lt;td class=&quot;xl68&quot; height=&quot;20&quot; style=&quot;border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; height: 15.0pt; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Clonazepam&lt;/td&gt;
  &lt;td class=&quot;xl69&quot; style=&quot;border-left: none; border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Sim&lt;/td&gt;
 &lt;/tr&gt;
&lt;tr height=&quot;20&quot; style=&quot;height: 15.0pt;&quot;&gt;
  &lt;td class=&quot;xl68&quot; height=&quot;20&quot; style=&quot;border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; height: 15.0pt; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Clonidina&lt;/td&gt;
  &lt;td class=&quot;xl69&quot; style=&quot;border-left: none; border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Sim&lt;/td&gt;
 &lt;/tr&gt;
&lt;tr height=&quot;20&quot; style=&quot;height: 15.0pt;&quot;&gt;
  &lt;td class=&quot;xl68&quot; height=&quot;20&quot; style=&quot;border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; height: 15.0pt; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Clorpromazina&lt;/td&gt;
  &lt;td class=&quot;xl69&quot; style=&quot;border-left: none; border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Não&lt;/td&gt;
 &lt;/tr&gt;
&lt;tr height=&quot;20&quot; style=&quot;height: 15.0pt;&quot;&gt;
  &lt;td class=&quot;xl68&quot; height=&quot;20&quot; style=&quot;border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; height: 15.0pt; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Dexametasona&lt;/td&gt;
  &lt;td class=&quot;xl69&quot; style=&quot;border-left: none; border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Sim&lt;/td&gt;
 &lt;/tr&gt;
&lt;tr height=&quot;20&quot; style=&quot;height: 15.0pt;&quot;&gt;
  &lt;td class=&quot;xl68&quot; height=&quot;20&quot; style=&quot;border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; height: 15.0pt; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Diclofenaco&lt;/td&gt;
  &lt;td class=&quot;xl69&quot; style=&quot;border-left: none; border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Sim&lt;/td&gt;
 &lt;/tr&gt;
&lt;tr height=&quot;20&quot; style=&quot;height: 15.0pt;&quot;&gt;
  &lt;td class=&quot;xl68&quot; height=&quot;20&quot; style=&quot;border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; height: 15.0pt; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Fenobarbital&lt;/td&gt;
  &lt;td class=&quot;xl69&quot; style=&quot;border-left: none; border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Sim&lt;/td&gt;
 &lt;/tr&gt;
&lt;tr height=&quot;20&quot; style=&quot;height: 15.0pt;&quot;&gt;
  &lt;td class=&quot;xl68&quot; height=&quot;20&quot; style=&quot;border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; height: 15.0pt; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Fentanil
  (citrato)&lt;/td&gt;
  &lt;td class=&quot;xl69&quot; style=&quot;border-left: none; border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Sim&lt;/td&gt;
 &lt;/tr&gt;
&lt;tr height=&quot;20&quot; style=&quot;height: 15.0pt;&quot;&gt;
  &lt;td class=&quot;xl68&quot; height=&quot;20&quot; style=&quot;border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; height: 15.0pt; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Furosemida&lt;/td&gt;
  &lt;td class=&quot;xl69&quot; style=&quot;border-left: none; border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Sim&lt;/td&gt;
 &lt;/tr&gt;
&lt;tr height=&quot;20&quot; style=&quot;height: 15.0pt;&quot;&gt;
  &lt;td class=&quot;xl68&quot; height=&quot;20&quot; style=&quot;border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; height: 15.0pt; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Haloperidol&lt;/td&gt;
  &lt;td class=&quot;xl69&quot; style=&quot;border-left: none; border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Sim&lt;/td&gt;
 &lt;/tr&gt;
&lt;tr height=&quot;20&quot; style=&quot;height: 15.0pt;&quot;&gt;
  &lt;td class=&quot;xl68&quot; height=&quot;20&quot; style=&quot;border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; height: 15.0pt; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Hidrocortisona&lt;/td&gt;
  &lt;td class=&quot;xl69&quot; style=&quot;border-left: none; border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Sim&lt;/td&gt;
 &lt;/tr&gt;
&lt;tr height=&quot;20&quot; style=&quot;height: 15.0pt;&quot;&gt;
  &lt;td class=&quot;xl68&quot; height=&quot;20&quot; style=&quot;border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; height: 15.0pt; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Hidroxizina&lt;/td&gt;
  &lt;td class=&quot;xl69&quot; style=&quot;border-left: none; border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Não&lt;/td&gt;
 &lt;/tr&gt;
&lt;tr height=&quot;20&quot; style=&quot;height: 15.0pt;&quot;&gt;
  &lt;td class=&quot;xl68&quot; height=&quot;20&quot; style=&quot;border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; height: 15.0pt; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Levomepromazina&lt;/td&gt;
  &lt;td class=&quot;xl69&quot; style=&quot;border-left: none; border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Sim&lt;/td&gt;
 &lt;/tr&gt;
&lt;tr height=&quot;20&quot; style=&quot;height: 15.0pt;&quot;&gt;
  &lt;td class=&quot;xl68&quot; height=&quot;20&quot; style=&quot;border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; height: 15.0pt; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Metadona&lt;/td&gt;
  &lt;td class=&quot;xl69&quot; style=&quot;border-left: none; border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Sim&lt;/td&gt;
 &lt;/tr&gt;
&lt;tr height=&quot;20&quot; style=&quot;height: 15.0pt;&quot;&gt;
  &lt;td class=&quot;xl68&quot; height=&quot;20&quot; style=&quot;border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; height: 15.0pt; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Metoclopramida&lt;/td&gt;
  &lt;td class=&quot;xl69&quot; style=&quot;border-left: none; border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Sim&lt;/td&gt;
 &lt;/tr&gt;
&lt;tr height=&quot;20&quot; style=&quot;height: 15.0pt;&quot;&gt;
  &lt;td class=&quot;xl68&quot; height=&quot;20&quot; style=&quot;border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; height: 15.0pt; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Midazolam&lt;/td&gt;
  &lt;td class=&quot;xl69&quot; style=&quot;border-left: none; border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Sim&lt;/td&gt;
 &lt;/tr&gt;
&lt;tr height=&quot;20&quot; style=&quot;height: 15.0pt;&quot;&gt;
  &lt;td class=&quot;xl68&quot; height=&quot;20&quot; style=&quot;border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; height: 15.0pt; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Morfina&lt;/td&gt;
  &lt;td class=&quot;xl69&quot; style=&quot;border-left: none; border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Sim&lt;/td&gt;
 &lt;/tr&gt;
&lt;tr height=&quot;20&quot; style=&quot;height: 15.0pt;&quot;&gt;
  &lt;td class=&quot;xl68&quot; height=&quot;20&quot; style=&quot;border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; height: 15.0pt; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Naloxona&lt;/td&gt;
  &lt;td class=&quot;xl69&quot; style=&quot;border-left: none; border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Sim&lt;/td&gt;
 &lt;/tr&gt;
&lt;tr height=&quot;20&quot; style=&quot;height: 15.0pt;&quot;&gt;
  &lt;td class=&quot;xl68&quot; height=&quot;20&quot; style=&quot;border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; height: 15.0pt; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Octreotida&lt;/td&gt;
  &lt;td class=&quot;xl69&quot; style=&quot;border-left: none; border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Sim&lt;/td&gt;
 &lt;/tr&gt;
&lt;tr height=&quot;20&quot; style=&quot;height: 15.0pt;&quot;&gt;
  &lt;td class=&quot;xl68&quot; height=&quot;20&quot; style=&quot;border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; height: 15.0pt; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Ondansetron&lt;/td&gt;
  &lt;td class=&quot;xl69&quot; style=&quot;border-left: none; border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Sim&lt;/td&gt;
 &lt;/tr&gt;
&lt;tr height=&quot;20&quot; style=&quot;height: 15.0pt;&quot;&gt;
  &lt;td class=&quot;xl68&quot; height=&quot;20&quot; style=&quot;border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; height: 15.0pt; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Oxicodona&lt;/td&gt;
  &lt;td class=&quot;xl69&quot; style=&quot;border-left: none; border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Sim&lt;/td&gt;
 &lt;/tr&gt;
&lt;tr height=&quot;20&quot; style=&quot;height: 15.0pt;&quot;&gt;
  &lt;td class=&quot;xl68&quot; height=&quot;20&quot; style=&quot;border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; height: 15.0pt; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Prometazina&lt;/td&gt;
  &lt;td class=&quot;xl69&quot; style=&quot;border-left: none; border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Sim&lt;/td&gt;
 &lt;/tr&gt;
&lt;tr height=&quot;20&quot; style=&quot;height: 15.0pt;&quot;&gt;
  &lt;td class=&quot;xl68&quot; height=&quot;20&quot; style=&quot;border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; height: 15.0pt; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Ranitidina&lt;/td&gt;
  &lt;td class=&quot;xl69&quot; style=&quot;border-left: none; border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Não
  há referências&lt;/td&gt;
 &lt;/tr&gt;
&lt;tr height=&quot;20&quot; style=&quot;height: 15.0pt;&quot;&gt;
  &lt;td class=&quot;xl68&quot; height=&quot;20&quot; style=&quot;border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; height: 15.0pt; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Tobramicina&lt;/td&gt;
  &lt;td class=&quot;xl69&quot; style=&quot;border-left: none; border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Sim&lt;/td&gt;
 &lt;/tr&gt;
&lt;tr height=&quot;20&quot; style=&quot;height: 15.0pt;&quot;&gt;
  &lt;td class=&quot;xl70&quot; height=&quot;20&quot; style=&quot;border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; height: 15.0pt; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Tramadol&lt;/td&gt;
  &lt;td class=&quot;xl71&quot; style=&quot;border-left: none; border-top: none; border: .5pt solid windowtext; color: black; font-family: Corbel; font-size: 11.0pt; font-weight: 400; text-decoration: none; text-line-through: none; text-underline-style: none;&quot;&gt;Sim&lt;/td&gt;
 &lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;</content><link rel='replies' type='application/atom+xml' href='http://helgabischoff.blogspot.com/feeds/7461760176485770685/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://helgabischoff.blogspot.com/2012/06/muitos-medicamentos-podem-ser.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/7461760176485770685'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/7461760176485770685'/><link rel='alternate' type='text/html' href='http://helgabischoff.blogspot.com/2012/06/muitos-medicamentos-podem-ser.html' title=''/><author><name>Helga Bischoff</name><uri>http://www.blogger.com/profile/08405263765684348837</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEihKVWoB58uUoLc7y6Qb9tkzXpeTsY_XFfn0-AufGMvESm9uBmZ5fzFANu4dshHkqmWyE9f0TmESGfuDsgaeSD0gOHMMnmm97FLV3i1B5Hl9lTpw7kQvqbn4G4-s6OJlfo/s220/foto+nova.png'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6740498378870516287.post-4604801057829936020</id><published>2012-05-09T16:32:00.003-07:00</published><updated>2012-05-09T16:32:31.437-07:00</updated><title type='text'>Descarte de medicamentos em casa</title><content type='html'>&lt;div style=&quot;background-color: white; color: #e06666;&quot;&gt;
&lt;b&gt;Segue um link do FDA sobre descarte de medicamentos, muito interessante!&lt;/b&gt;&lt;/div&gt;
&lt;div style=&quot;background-color: white; color: #e06666;&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div style=&quot;background-color: white; color: #e06666;&quot;&gt;
&lt;b&gt;&lt;a href=&quot;http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/EnsuringSafeUseofMedicine/SafeDisposalofMedicines/ucm186187.htm#MEDICINES&quot;&gt;http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/EnsuringSafeUseofMedicine/SafeDisposalofMedicines/ucm186187.htm#MEDICINES &lt;/a&gt;&lt;/b&gt;&lt;/div&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;</content><link rel='replies' type='application/atom+xml' href='http://helgabischoff.blogspot.com/feeds/4604801057829936020/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://helgabischoff.blogspot.com/2012/05/descarte-de-medicamentos-em-casa.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/4604801057829936020'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/4604801057829936020'/><link rel='alternate' type='text/html' href='http://helgabischoff.blogspot.com/2012/05/descarte-de-medicamentos-em-casa.html' title='Descarte de medicamentos em casa'/><author><name>Helga Bischoff</name><uri>http://www.blogger.com/profile/08405263765684348837</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEihKVWoB58uUoLc7y6Qb9tkzXpeTsY_XFfn0-AufGMvESm9uBmZ5fzFANu4dshHkqmWyE9f0TmESGfuDsgaeSD0gOHMMnmm97FLV3i1B5Hl9lTpw7kQvqbn4G4-s6OJlfo/s220/foto+nova.png'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6740498378870516287.post-5819509687379587457</id><published>2012-04-25T15:32:00.001-07:00</published><updated>2012-04-25T15:32:40.523-07:00</updated><title type='text'>Fenitoína em pacientes com hipoalbuminemia</title><content type='html'>&lt;div style=&quot;font-family: Arial,Helvetica,sans-serif; text-align: justify;&quot;&gt;
&amp;nbsp;&amp;nbsp; &lt;b&gt;&lt;span style=&quot;color: #351c75;&quot;&gt;A fenitoína tem grande afinidade por proteínas, principalmente pela albumina. Com isso, pacientes que estão com hipoalbuminemia terão uma fração de fenitoína livre maior. Mas no que isso implica? Ao realizarmos a dosagem sérica de fenitoína, o resultado pode aparentemente estar dentro dos limites desejados, porém, não podemos deixar de levar em consideração a hipoalbuminemia. A fórmula de &lt;/span&gt;&lt;span class=&quot;st&quot; style=&quot;color: #351c75;&quot;&gt;Sheiner- Tozer permite que se tenha uma concentração sérica corrigida de fenitoína para pacientes com hipoalbuminemia.&lt;/span&gt;&lt;/b&gt;&lt;/div&gt;
&lt;div style=&quot;color: #351c75; font-family: Arial,Helvetica,sans-serif; text-align: justify;&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div style=&quot;color: #351c75; font-family: Arial,Helvetica,sans-serif; text-align: justify;&quot;&gt;
&lt;!--[if gte mso 9]&gt;&lt;xml&gt;
 &lt;o:OfficeDocumentSettings&gt;
  &lt;o:AllowPNG/&gt;
 &lt;/o:OfficeDocumentSettings&gt;
&lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;
 &lt;w:WordDocument&gt;
  &lt;w:View&gt;Normal&lt;/w:View&gt;
  &lt;w:Zoom&gt;0&lt;/w:Zoom&gt;
  &lt;w:TrackMoves/&gt;
  &lt;w:TrackFormatting/&gt;
  &lt;w:HyphenationZone&gt;21&lt;/w:HyphenationZone&gt;
  &lt;w:PunctuationKerning/&gt;
  &lt;w:ValidateAgainstSchemas/&gt;
  &lt;w:SaveIfXMLInvalid&gt;false&lt;/w:SaveIfXMLInvalid&gt;
  &lt;w:IgnoreMixedContent&gt;false&lt;/w:IgnoreMixedContent&gt;
  &lt;w:AlwaysShowPlaceholderText&gt;false&lt;/w:AlwaysShowPlaceholderText&gt;
  &lt;w:DoNotPromoteQF/&gt;
  &lt;w:LidThemeOther&gt;PT-BR&lt;/w:LidThemeOther&gt;
  &lt;w:LidThemeAsian&gt;X-NONE&lt;/w:LidThemeAsian&gt;
  &lt;w:LidThemeComplexScript&gt;X-NONE&lt;/w:LidThemeComplexScript&gt;
  &lt;w:Compatibility&gt;
   &lt;w:BreakWrappedTables/&gt;
   &lt;w:SnapToGridInCell/&gt;
   &lt;w:WrapTextWithPunct/&gt;
   &lt;w:UseAsianBreakRules/&gt;
   &lt;w:DontGrowAutofit/&gt;
   &lt;w:SplitPgBreakAndParaMark/&gt;
   &lt;w:EnableOpenTypeKerning/&gt;
   &lt;w:DontFlipMirrorIndents/&gt;
   &lt;w:OverrideTableStyleHps/&gt;
  &lt;/w:Compatibility&gt;
  &lt;m:mathPr&gt;
   &lt;m:mathFont m:val=&quot;Cambria Math&quot;/&gt;
   &lt;m:brkBin m:val=&quot;before&quot;/&gt;
   &lt;m:brkBinSub m:val=&quot;&amp;#45;-&quot;/&gt;
   &lt;m:smallFrac m:val=&quot;off&quot;/&gt;
   &lt;m:dispDef/&gt;
   &lt;m:lMargin m:val=&quot;0&quot;/&gt;
   &lt;m:rMargin m:val=&quot;0&quot;/&gt;
   &lt;m:defJc m:val=&quot;centerGroup&quot;/&gt;
   &lt;m:wrapIndent m:val=&quot;1440&quot;/&gt;
   &lt;m:intLim m:val=&quot;subSup&quot;/&gt;
   &lt;m:naryLim m:val=&quot;undOvr&quot;/&gt;
  &lt;/m:mathPr&gt;&lt;/w:WordDocument&gt;
&lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;
 &lt;w:LatentStyles DefLockedState=&quot;false&quot; DefUnhideWhenUsed=&quot;true&quot;
  DefSemiHidden=&quot;true&quot; DefQFormat=&quot;false&quot; DefPriority=&quot;99&quot;
  LatentStyleCount=&quot;267&quot;&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;0&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Normal&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;heading 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 7&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 8&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 9&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 7&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 8&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 9&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;35&quot; QFormat=&quot;true&quot; Name=&quot;caption&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;10&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Title&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;1&quot; Name=&quot;Default Paragraph Font&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;11&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Subtitle&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;22&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Strong&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;20&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Emphasis&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;59&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Table Grid&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; UnhideWhenUsed=&quot;false&quot; Name=&quot;Placeholder Text&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;1&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;No Spacing&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; UnhideWhenUsed=&quot;false&quot; Name=&quot;Revision&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;34&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;List Paragraph&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;29&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Quote&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;30&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Intense Quote&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;19&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Subtle Emphasis&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;21&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Intense Emphasis&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;31&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Subtle Reference&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;32&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Intense Reference&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;33&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Book Title&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;37&quot; Name=&quot;Bibliography&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; QFormat=&quot;true&quot; Name=&quot;TOC Heading&quot;/&gt;
 &lt;/w:LatentStyles&gt;
&lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 10]&gt;
&lt;style&gt;
 /* Style Definitions */
 table.MsoNormalTable
 {mso-style-name:&quot;Tabela normal&quot;;
 mso-tstyle-rowband-size:0;
 mso-tstyle-colband-size:0;
 mso-style-noshow:yes;
 mso-style-priority:99;
 mso-style-parent:&quot;&quot;;
 mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
 mso-para-margin-top:0cm;
 mso-para-margin-right:0cm;
 mso-para-margin-bottom:10.0pt;
 mso-para-margin-left:0cm;
 line-height:115%;
 mso-pagination:widow-orphan;
 font-size:11.0pt;
 font-family:&quot;Calibri&quot;,&quot;sans-serif&quot;;
 mso-ascii-font-family:Calibri;
 mso-ascii-theme-font:minor-latin;
 mso-hansi-font-family:Calibri;
 mso-hansi-theme-font:minor-latin;
 mso-bidi-font-family:&quot;Times New Roman&quot;;
 mso-bidi-theme-font:minor-bidi;
 mso-fareast-language:EN-US;}
&lt;/style&gt;
&lt;![endif]--&gt;

&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;color: #351c75; font-family: Arial,Helvetica,sans-serif; text-align: center;&quot;&gt;
&lt;b&gt;C corrigida fenitoína = &lt;span style=&quot;mso-spacerun: yes;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;u&gt;&lt;span style=&quot;mso-spacerun: yes;&quot;&gt; &amp;nbsp;&amp;nbsp;&amp;nbsp; &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/span&gt;C sérica de fenitoína&lt;span style=&quot;mso-spacerun: yes;&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/span&gt;&lt;/u&gt;&lt;/b&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;color: #351c75; font-family: Arial,Helvetica,sans-serif; text-align: center;&quot;&gt;
&lt;b&gt;&lt;span style=&quot;mso-spacerun: yes;&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &amp;nbsp; &amp;nbsp;&amp;nbsp; &lt;/span&gt;0,2 x
C sérica albumina + 0,1&lt;/b&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;color: #351c75; font-family: Arial,Helvetica,sans-serif; text-align: center;&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;color: #351c75; font-family: Arial,Helvetica,sans-serif; text-align: center;&quot;&gt;
&lt;b&gt;Onde: &lt;span style=&quot;mso-spacerun: yes;&quot;&gt;&amp;nbsp;&lt;/span&gt;C =
Concentração&lt;/b&gt;&lt;/div&gt;
&lt;div style=&quot;color: #351c75; font-family: Arial,Helvetica,sans-serif; text-align: justify;&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div style=&quot;color: #351c75; font-family: Arial,Helvetica,sans-serif; text-align: justify;&quot;&gt;
&lt;b&gt;&amp;nbsp; A fenitoína é um medicamento antiepiléptico que em doses tóxicas pode ser letal, portanto é aconselhado um acompanhamento pelo farmacêutico clínico da dosagem sérica da mesma bem como da albumina e,quando necessário,&amp;nbsp; fazer as sugestões de ajuste de dose junto à equipe médica.&lt;/b&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://helgabischoff.blogspot.com/feeds/5819509687379587457/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://helgabischoff.blogspot.com/2012/04/fenitoina-em-pacientes-com.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/5819509687379587457'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/5819509687379587457'/><link rel='alternate' type='text/html' href='http://helgabischoff.blogspot.com/2012/04/fenitoina-em-pacientes-com.html' title='Fenitoína em pacientes com hipoalbuminemia'/><author><name>Helga Bischoff</name><uri>http://www.blogger.com/profile/08405263765684348837</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEihKVWoB58uUoLc7y6Qb9tkzXpeTsY_XFfn0-AufGMvESm9uBmZ5fzFANu4dshHkqmWyE9f0TmESGfuDsgaeSD0gOHMMnmm97FLV3i1B5Hl9lTpw7kQvqbn4G4-s6OJlfo/s220/foto+nova.png'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6740498378870516287.post-6562087431022979903</id><published>2012-04-07T16:54:00.000-07:00</published><updated>2012-04-07T16:54:25.677-07:00</updated><title type='text'>Cálculo de Área da Superfície Corpórea</title><content type='html'>&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;o:OfficeDocumentSettings&gt;   &lt;o:RelyOnVML/&gt;   &lt;o:AllowPNG/&gt;  &lt;/o:OfficeDocumentSettings&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;w:WordDocument&gt;   &lt;w:View&gt;Normal&lt;/w:View&gt;   &lt;w:Zoom&gt;0&lt;/w:Zoom&gt;   &lt;w:TrackMoves/&gt;   &lt;w:TrackFormatting/&gt;   &lt;w:HyphenationZone&gt;21&lt;/w:HyphenationZone&gt;   &lt;w:PunctuationKerning/&gt;   &lt;w:ValidateAgainstSchemas/&gt;   &lt;w:SaveIfXMLInvalid&gt;false&lt;/w:SaveIfXMLInvalid&gt;   &lt;w:IgnoreMixedContent&gt;false&lt;/w:IgnoreMixedContent&gt;   &lt;w:AlwaysShowPlaceholderText&gt;false&lt;/w:AlwaysShowPlaceholderText&gt;   &lt;w:DoNotPromoteQF/&gt;   &lt;w:LidThemeOther&gt;PT-BR&lt;/w:LidThemeOther&gt;   &lt;w:LidThemeAsian&gt;X-NONE&lt;/w:LidThemeAsian&gt;   &lt;w:LidThemeComplexScript&gt;X-NONE&lt;/w:LidThemeComplexScript&gt;   &lt;w:Compatibility&gt;    &lt;w:BreakWrappedTables/&gt;    &lt;w:SnapToGridInCell/&gt;    &lt;w:WrapTextWithPunct/&gt;    &lt;w:UseAsianBreakRules/&gt;    &lt;w:DontGrowAutofit/&gt;    &lt;w:SplitPgBreakAndParaMark/&gt;    &lt;w:EnableOpenTypeKerning/&gt;    &lt;w:DontFlipMirrorIndents/&gt;    &lt;w:OverrideTableStyleHps/&gt;   &lt;/w:Compatibility&gt;   &lt;m:mathPr&gt;    &lt;m:mathFont m:val=&quot;Cambria Math&quot;/&gt;    &lt;m:brkBin m:val=&quot;before&quot;/&gt;    &lt;m:brkBinSub m:val=&quot;&amp;#45;-&quot;/&gt;    &lt;m:smallFrac m:val=&quot;off&quot;/&gt;    &lt;m:dispDef/&gt;    &lt;m:lMargin m:val=&quot;0&quot;/&gt;    &lt;m:rMargin m:val=&quot;0&quot;/&gt;    &lt;m:defJc m:val=&quot;centerGroup&quot;/&gt;    &lt;m:wrapIndent m:val=&quot;1440&quot;/&gt;    &lt;m:intLim m:val=&quot;subSup&quot;/&gt;    &lt;m:naryLim m:val=&quot;undOvr&quot;/&gt;   &lt;/m:mathPr&gt;&lt;/w:WordDocument&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;w:LatentStyles DefLockedState=&quot;false&quot; DefUnhideWhenUsed=&quot;true&quot;
  DefSemiHidden=&quot;true&quot; DefQFormat=&quot;false&quot; DefPriority=&quot;99&quot;
  LatentStyleCount=&quot;267&quot;&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;0&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Normal&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;heading 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 7&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 8&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 9&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 7&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 8&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 9&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;35&quot; QFormat=&quot;true&quot; Name=&quot;caption&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;10&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Title&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;1&quot; Name=&quot;Default Paragraph Font&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;11&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Subtitle&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;22&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Strong&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;20&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Emphasis&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;59&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Table Grid&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; UnhideWhenUsed=&quot;false&quot; Name=&quot;Placeholder Text&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;1&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;No Spacing&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; UnhideWhenUsed=&quot;false&quot; Name=&quot;Revision&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;34&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;List Paragraph&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;29&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Quote&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;30&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Intense Quote&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 1&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 2&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 3&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 4&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 5&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 6&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;19&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Subtle Emphasis&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;21&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Intense Emphasis&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;31&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Subtle Reference&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;32&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Intense Reference&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;33&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Book Title&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;37&quot; Name=&quot;Bibliography&quot;/&gt;   &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; QFormat=&quot;true&quot; Name=&quot;TOC Heading&quot;/&gt;  &lt;/w:LatentStyles&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 10]&gt; &lt;style&gt;
 /* Style Definitions */
 table.MsoNormalTable
 {mso-style-name:&quot;Tabela normal&quot;;
 mso-tstyle-rowband-size:0;
 mso-tstyle-colband-size:0;
 mso-style-noshow:yes;
 mso-style-priority:99;
 mso-style-parent:&quot;&quot;;
 mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
 mso-para-margin-top:0cm;
 mso-para-margin-right:0cm;
 mso-para-margin-bottom:10.0pt;
 mso-para-margin-left:0cm;
 line-height:115%;
 mso-pagination:widow-orphan;
 font-size:11.0pt;
 font-family:&quot;Calibri&quot;,&quot;sans-serif&quot;;
 mso-ascii-font-family:Calibri;
 mso-ascii-theme-font:minor-latin;
 mso-hansi-font-family:Calibri;
 mso-hansi-theme-font:minor-latin;
 mso-bidi-font-family:&quot;Times New Roman&quot;;
 mso-bidi-theme-font:minor-bidi;
 mso-fareast-language:EN-US;}
&lt;/style&gt; &lt;![endif]--&gt;  &lt;br /&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;color: blue; font-family: Arial,Helvetica,sans-serif; line-height: normal; text-align: justify; text-indent: 35.4pt;&quot;&gt;O cálculo da Área da Superfície Corpórea (ASC) é melhor indicador metabólico que o peso, pois ocorre menos interferência da massa adiposa. Alguns medicamentos requerem o cálculo da área da superfície corpórea para que se possa calcular a dose exata para determinada criança. Existem estudos que recomendam, caso a criança pesar mais de 10 Kg, calcular a dose do medicamento levando em consideração a área da superfície corpórea e não o peso. Para crianças, a fórmula utilizada para calcular a Área da Superfície Corpórea é a de Haycock:&lt;/div&gt;&lt;div class=&quot;MsoNormal&quot; style=&quot;color: blue; font-family: Arial,Helvetica,sans-serif; line-height: normal; text-align: center;&quot;&gt;&lt;b&gt;ASC= 0,024265*Peso (Kg)&lt;sup&gt;0,5378&lt;/sup&gt;*Altura(cm)&lt;sup&gt;0,3964&lt;/sup&gt;&lt;/b&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://helgabischoff.blogspot.com/feeds/6562087431022979903/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://helgabischoff.blogspot.com/2012/04/calculo-de-area-da-superficie-corporea.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/6562087431022979903'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/6562087431022979903'/><link rel='alternate' type='text/html' href='http://helgabischoff.blogspot.com/2012/04/calculo-de-area-da-superficie-corporea.html' title='Cálculo de Área da Superfície Corpórea'/><author><name>Helga Bischoff</name><uri>http://www.blogger.com/profile/08405263765684348837</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEihKVWoB58uUoLc7y6Qb9tkzXpeTsY_XFfn0-AufGMvESm9uBmZ5fzFANu4dshHkqmWyE9f0TmESGfuDsgaeSD0gOHMMnmm97FLV3i1B5Hl9lTpw7kQvqbn4G4-s6OJlfo/s220/foto+nova.png'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6740498378870516287.post-3814381966808602754</id><published>2011-08-27T07:00:00.000-07:00</published><updated>2011-08-27T07:00:22.392-07:00</updated><title type='text'>Interação Medicamentosa - Valproato + Meropenem</title><content type='html'>&lt;div style=&quot;text-align: justify;&quot;&gt;&lt;span style=&quot;color: #b45f06;&quot;&gt;&lt;strong&gt;Pacientes que fazem uso crônico de medicamentos devem sempre lembrar de que as interações medicamentosas existem e podem ocorrer, mesmo quando se faz uso há muito tempo de determinados medicamentos.&amp;nbsp;Um medicamento de uso crônico, que já está com sua dose estabilizada e confirmada através do&amp;nbsp;nível sérico, pode desestabilizar no momento em que uma nova terapia for agregada. Um exemplo disso é o caso dos pacientes que fazem uso de valproato de sódio.&amp;nbsp;Se este paciente apresentar uma infecção e precisar receber por exemplo, meropenem ou ertapenem, deve-se ficar atento, pois estes antibióticos podem diminuir o nível sérico de valproato. Já verifiquei esta interação na prática, e, para que o paciente não corra o risco de ter uma crise epiléptica, deve-se substituir o antibiótico ou&amp;nbsp;o anticonvulsivante. Ao realizar a substituição, sempre devemos verificar se uma nova interação não poderá ocorrer. &lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://helgabischoff.blogspot.com/feeds/3814381966808602754/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://helgabischoff.blogspot.com/2011/08/interacao-medicamentosa-valproato.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/3814381966808602754'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/3814381966808602754'/><link rel='alternate' type='text/html' href='http://helgabischoff.blogspot.com/2011/08/interacao-medicamentosa-valproato.html' title='Interação Medicamentosa - Valproato + Meropenem'/><author><name>Helga Bischoff</name><uri>http://www.blogger.com/profile/08405263765684348837</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEihKVWoB58uUoLc7y6Qb9tkzXpeTsY_XFfn0-AufGMvESm9uBmZ5fzFANu4dshHkqmWyE9f0TmESGfuDsgaeSD0gOHMMnmm97FLV3i1B5Hl9lTpw7kQvqbn4G4-s6OJlfo/s220/foto+nova.png'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6740498378870516287.post-6250339232539685494</id><published>2011-08-17T16:50:00.001-07:00</published><updated>2011-08-17T16:50:35.211-07:00</updated><title type='text'>Farmacêutico deve se mostrar</title><content type='html'>&lt;a href=&quot;http://g1.globo.com/ciencia-e-saude/noticia/2011/08/farmaceutico-deve-se-mostrar-diz-americana-sobre-profissao-no-brasil.html?&amp;amp;utm_source=akna&amp;amp;utm_medium=email&amp;amp;utm_campaign=Clipping+-+17%2F08%2F2011&quot;&gt;http://g1.globo.com/ciencia-e-saude/noticia/2011/08/farmaceutico-deve-se-mostrar-diz-americana-sobre-profissao-no-brasil.html?&amp;amp;utm_source=akna&amp;amp;utm_medium=email&amp;amp;utm_campaign=Clipping+-+17%2F08%2F2011&lt;/a&gt;&lt;br /&gt;
</content><link rel='replies' type='application/atom+xml' href='http://helgabischoff.blogspot.com/feeds/6250339232539685494/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://helgabischoff.blogspot.com/2011/08/farmaceutico-deve-se-mostrar.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/6250339232539685494'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/6250339232539685494'/><link rel='alternate' type='text/html' href='http://helgabischoff.blogspot.com/2011/08/farmaceutico-deve-se-mostrar.html' title='Farmacêutico deve se mostrar'/><author><name>Helga Bischoff</name><uri>http://www.blogger.com/profile/08405263765684348837</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEihKVWoB58uUoLc7y6Qb9tkzXpeTsY_XFfn0-AufGMvESm9uBmZ5fzFANu4dshHkqmWyE9f0TmESGfuDsgaeSD0gOHMMnmm97FLV3i1B5Hl9lTpw7kQvqbn4G4-s6OJlfo/s220/foto+nova.png'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6740498378870516287.post-5300851270331607984</id><published>2011-06-28T16:38:00.000-07:00</published><updated>2011-06-28T16:38:46.824-07:00</updated><title type='text'>Cafeína e Aminofilina em apnéia neonatal</title><content type='html'>&lt;div style=&quot;text-align: justify;&quot;&gt;&lt;b style=&quot;color: #666666;&quot;&gt;A apnéia é um dos distúrbios respiratórios mais frequentes no periodo neonatal. Se não for reconhecida rapidamente, o bebê pode evoluir com bradicardia e cianose, correndo risco de vida. Ocorre com mais frequencia em bebês de baixo peso. O tratamento deve ser farmacológico. O tratamento mais utilizado sempre foi com aminofilina, porém, nos dias de hoje, sabemos que a cafeína tornou-se a droga de escolha. A cafeína possui meia vida mais longa, isso possibilita que a dose seja administrada apenas 1 vez ao dia, ao contrário da aminofilina que deve ser administrada em torno de 3 vezes ao dia. A aminofilina possui janela terapêutica estreita, ou seja, a dose tóxica é muito próxima da dose terapêutica. Com isso, para obtermos um uso seguro de aminofilina, recomenda-se o controle através da dosagem do nível sérico, que deve ser realizado sempre no &quot;vale&quot;. Estudos indicam que a cafeína proporciona menos efeitos adversos do que a aminofilina. O único problema é que no Brasil ainda não dispomos de uma forma comercial&amp;nbsp; em ampola para ser adquirida. Porém, existem alguns laboratórios de manipulação de injetáveis que produzem a cafeína na forma de citrato sob encomenda. A dose recomendada de citrato de cafeína para tratar apnéia neonatal é de 20 mg/kg/dia (dose de ataque), seguida de 5 mg/kg/dia (dose de manutenção).&lt;/b&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://helgabischoff.blogspot.com/feeds/5300851270331607984/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://helgabischoff.blogspot.com/2011/06/cafeina-e-aminofilina-em-apneia.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/5300851270331607984'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/5300851270331607984'/><link rel='alternate' type='text/html' href='http://helgabischoff.blogspot.com/2011/06/cafeina-e-aminofilina-em-apneia.html' title='Cafeína e Aminofilina em apnéia neonatal'/><author><name>Helga Bischoff</name><uri>http://www.blogger.com/profile/08405263765684348837</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEihKVWoB58uUoLc7y6Qb9tkzXpeTsY_XFfn0-AufGMvESm9uBmZ5fzFANu4dshHkqmWyE9f0TmESGfuDsgaeSD0gOHMMnmm97FLV3i1B5Hl9lTpw7kQvqbn4G4-s6OJlfo/s220/foto+nova.png'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6740498378870516287.post-6223118799018160045</id><published>2011-04-17T15:52:00.000-07:00</published><updated>2011-04-17T15:52:11.191-07:00</updated><title type='text'>Atenção farmacêutica ao paciente asmático</title><content type='html'>&lt;div style=&quot;text-align: justify;&quot;&gt;&lt;b style=&quot;color: #e06666;&quot;&gt;Hoje em dia, o número de pessoas com problemas respiratórios tem aumentado, principalmente nas grandes cidades, devido ao agravamento da poluição e mudanças climáticas. O tratamento para asmáticos se dá muitas vezes, por meio de dispositivos inalatórios (spay, turbuhaler, handihaler, etc). O tratamento com corticóide inalatório de mostra muito eficaz, e melhor ainda com broncodilatador associado. O único problema é que estes dispositivos nem sempre são fáceis de se utilizar, e, dependendo da situação, acaba ocorrendo descontinuação do tratamento. Nesta hora, cabe ao farmacêutico realizar um acompanhamento mais de perto com este tipo de paciente. Além da orientação quanto ao uso,&amp;nbsp; deve-se dispor de um instrumento de medida (algoritmo) para que se possa avaliar se o paciente está fazendo uso de maneira correta destes medicamentos. Minha monografia da especialização foi neste tema, e, posso afirmar que dos pacientes que acompanhei, 100% têm dificuldade em utilizar dispositivos spray (bombinhas) sem o espaçador. Já os dispositivos tipo handihaler e turbuhaler, apesar de parecerem mais complexos, permitem que o paciente faça uso de forma correta após uma boa orientação do farmacêutico.&lt;/b&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://helgabischoff.blogspot.com/feeds/6223118799018160045/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://helgabischoff.blogspot.com/2011/04/atencao-farmaceutica-ao-paciente.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/6223118799018160045'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/6223118799018160045'/><link rel='alternate' type='text/html' href='http://helgabischoff.blogspot.com/2011/04/atencao-farmaceutica-ao-paciente.html' title='Atenção farmacêutica ao paciente asmático'/><author><name>Helga Bischoff</name><uri>http://www.blogger.com/profile/08405263765684348837</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEihKVWoB58uUoLc7y6Qb9tkzXpeTsY_XFfn0-AufGMvESm9uBmZ5fzFANu4dshHkqmWyE9f0TmESGfuDsgaeSD0gOHMMnmm97FLV3i1B5Hl9lTpw7kQvqbn4G4-s6OJlfo/s220/foto+nova.png'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6740498378870516287.post-8127526064377212989</id><published>2011-03-29T17:18:00.000-07:00</published><updated>2011-03-29T17:18:28.008-07:00</updated><title type='text'>Imunossupressores e teratogenicidade</title><content type='html'>&lt;div style=&quot;text-align: left;&quot;&gt;&lt;b&gt;&lt;span style=&quot;color: blue;&quot;&gt;Os medicamentos imunossupressores são esquema terapêutico básico para qualquer paciente transplantado, porém, vale lembrar que estes medicamentos possuem propriedades teratogênicas. Em hospitais onde existem muitos pacientes que fazem uso destes medicamentos, a equipe de enfermagem deve estar preparada na hora da medicação. Por exemplo, se um paciente toma meio comprimido de determinado imunossupressor, e a farmácia do hospital não manda fracionado, caberá a enfermagem fazê-lo. Como estes medicamentos são teratogênicos e muitas vezes citotóxicos, os cuidados devem ser os mesmos que tomamos para com medicamentos desta classe. Ao partir um comprimido, partículas ficam dispersas no ar, e, com o passar do tempo, ao inalar diversas vezes estas partículas, estaremos mais sucetíveis a desenvolver doenças em decorrência da citotoxicidade. Mulheres grávidas não devem manipular estes medicamentos, devido ao risco de teratogenicidade. O ideal é dispor de um ambiente com fluxo laminar para que se possa fracionar estas doses. &lt;/span&gt;&lt;/b&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://helgabischoff.blogspot.com/feeds/8127526064377212989/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://helgabischoff.blogspot.com/2011/03/imunossupressores-e-teratogenicidade.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/8127526064377212989'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/8127526064377212989'/><link rel='alternate' type='text/html' href='http://helgabischoff.blogspot.com/2011/03/imunossupressores-e-teratogenicidade.html' title='Imunossupressores e teratogenicidade'/><author><name>Helga Bischoff</name><uri>http://www.blogger.com/profile/08405263765684348837</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEihKVWoB58uUoLc7y6Qb9tkzXpeTsY_XFfn0-AufGMvESm9uBmZ5fzFANu4dshHkqmWyE9f0TmESGfuDsgaeSD0gOHMMnmm97FLV3i1B5Hl9lTpw7kQvqbn4G4-s6OJlfo/s220/foto+nova.png'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6740498378870516287.post-7744612143682891306</id><published>2011-02-13T05:49:00.000-08:00</published><updated>2011-02-13T05:49:17.742-08:00</updated><title type='text'>Anamnese Farmacêutica em Neonatologia</title><content type='html'>&lt;div style=&quot;text-align: justify;&quot;&gt;&lt;span style=&quot;color: red; font-family: Arial, Helvetica, sans-serif;&quot;&gt;&lt;strong&gt;Sempre que estudamos sobre anamnese farmacêutica, lembramos que devemos ter um formulário padronizado que contemple perguntas simples de serem respondidas em um curto espaço de tempo. A anamnese deve proporcionar ao farmacêutico conhecer toda a história do paciente, principalmente no que diz repeito ao tratamento farmacológico já utilizado. Por isso, torna-se de extrema importância para aqueles que trabalham com neonatos, que fiquem atentos ao detalhe de que, nestes casos, além de realizar a anamnese do bebê, é necessário também investigar a mãe do bebê, principalmente se ela ainda estiver amamentando, pois a grande maioria dos medicamentos pode passar para o bebê através do leite materno. Muitas mães desconhecem que isso pode ocorrer, por isso, além de realizar a anamnese, torna-se importante que seja realizado um trabalho de orientação destas mães, para que elas possam utilizar medicamentos de forma segura, sem prejudicar&amp;nbsp;seu tratamento e&amp;nbsp;a saúde do bebê.&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://helgabischoff.blogspot.com/feeds/7744612143682891306/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://helgabischoff.blogspot.com/2011/02/anamnese-farmaceutica-em-neonatologia.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/7744612143682891306'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/7744612143682891306'/><link rel='alternate' type='text/html' href='http://helgabischoff.blogspot.com/2011/02/anamnese-farmaceutica-em-neonatologia.html' title='Anamnese Farmacêutica em Neonatologia'/><author><name>Helga Bischoff</name><uri>http://www.blogger.com/profile/08405263765684348837</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEihKVWoB58uUoLc7y6Qb9tkzXpeTsY_XFfn0-AufGMvESm9uBmZ5fzFANu4dshHkqmWyE9f0TmESGfuDsgaeSD0gOHMMnmm97FLV3i1B5Hl9lTpw7kQvqbn4G4-s6OJlfo/s220/foto+nova.png'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6740498378870516287.post-5788995737579608753</id><published>2011-01-20T13:48:00.000-08:00</published><updated>2011-01-20T13:48:52.453-08:00</updated><title type='text'>Entrevista</title><content type='html'>&lt;b style=&quot;color: purple;&quot;&gt;Segue entrevista publicada na Revista dos Farmacêuticos n. 100 sobre Cuidados Paliativos, na página 50. &lt;/b&gt;&lt;br /&gt;
&lt;br /&gt;
&lt;a href=&quot;http://issuu.com/crfsp/docs/rf-100&quot;&gt;http://issuu.com/crfsp/docs/rf-100&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='http://helgabischoff.blogspot.com/feeds/5788995737579608753/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://helgabischoff.blogspot.com/2011/01/entrevista.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/5788995737579608753'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/5788995737579608753'/><link rel='alternate' type='text/html' href='http://helgabischoff.blogspot.com/2011/01/entrevista.html' title='Entrevista'/><author><name>Helga Bischoff</name><uri>http://www.blogger.com/profile/08405263765684348837</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEihKVWoB58uUoLc7y6Qb9tkzXpeTsY_XFfn0-AufGMvESm9uBmZ5fzFANu4dshHkqmWyE9f0TmESGfuDsgaeSD0gOHMMnmm97FLV3i1B5Hl9lTpw7kQvqbn4G4-s6OJlfo/s220/foto+nova.png'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6740498378870516287.post-5088668711378191148</id><published>2010-10-16T10:31:00.000-07:00</published><updated>2010-10-16T10:31:02.044-07:00</updated><title type='text'>Escala de utilização de laxantes em cuidados paliativos</title><content type='html'>&lt;div style=&quot;text-align: justify;&quot;&gt;&lt;em&gt;&lt;strong&gt;&lt;span style=&quot;color: #e69138;&quot;&gt;Este mês participei do Congresso Internacional de Cuidados Paliativos da ANCP e levei um trabalho na forma de pôster. O trabalho é uma proposta de Escala de Utilização de Laxantes em Cuidados Paliativos. Sabemos que muitos pacientes em cuidados paliativos apresentam constipação intestinal, mas qual o melhor laxante a ser usado em cada caso? Neste trabalho apresentamos uma proposta, onde o levantamento foi feito a partir de artigos científicos desde 2000 até 2010. Consultamos também monografias dos medimentos e diretrizes em cuidados paliativos. Esta escala mostra-se útil para aplicação da equipe multiprofissional, pois torna fácil a decisão de qual laxante usar.&lt;/span&gt;&lt;/strong&gt;&lt;/em&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://helgabischoff.blogspot.com/feeds/5088668711378191148/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://helgabischoff.blogspot.com/2010/10/escala-de-utilizacao-de-laxantes-em.html#comment-form' title='1 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/5088668711378191148'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/5088668711378191148'/><link rel='alternate' type='text/html' href='http://helgabischoff.blogspot.com/2010/10/escala-de-utilizacao-de-laxantes-em.html' title='Escala de utilização de laxantes em cuidados paliativos'/><author><name>Helga Bischoff</name><uri>http://www.blogger.com/profile/08405263765684348837</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEihKVWoB58uUoLc7y6Qb9tkzXpeTsY_XFfn0-AufGMvESm9uBmZ5fzFANu4dshHkqmWyE9f0TmESGfuDsgaeSD0gOHMMnmm97FLV3i1B5Hl9lTpw7kQvqbn4G4-s6OJlfo/s220/foto+nova.png'/></author><thr:total>1</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6740498378870516287.post-4056184367211715457</id><published>2010-09-01T18:10:00.000-07:00</published><updated>2010-09-01T18:10:33.866-07:00</updated><title type='text'>Valproato de Sódio</title><content type='html'>&lt;div style=&quot;text-align: justify;&quot;&gt;&lt;span style=&quot;color: #8e7cc3; font-family: Arial, Helvetica, sans-serif;&quot;&gt;&lt;strong&gt;O valproato é muito utilizado para tratamento de epilepsia, porém, em algumas situações, ele pode não ser efetivo. Um exemplo prático ocorreu comigo esses dias, uma paciente fazia uso deste medicamento e estava recebendo uma série de outros medicamentos, entre eles meropenem. Ao analisar a prescrição, constatei uma interação entre o valproato e meropenem, onde pode ocorrer redução dos níveis de valproato, podendo chegar até a uma perda do efeito anticonvulsivo. A dosagem sérica de ácido valpróico demonstrou que de fato a interação estava ocorrendo. Uma opção nestes casos, seria a substituição de valproato por outro anticonvulsivo, como por exemplo a etussuximida, medicamento novo ainda no Brasil. Este medicamento não interage com esta classe de antibíóticos, mostrando-se uma boa&amp;nbsp;alternativa. A etussuximida também pode ser dosada para confirmação dos níveis séricos.&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://helgabischoff.blogspot.com/feeds/4056184367211715457/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://helgabischoff.blogspot.com/2010/09/valproato-de-sodio.html#comment-form' title='1 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/4056184367211715457'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/4056184367211715457'/><link rel='alternate' type='text/html' href='http://helgabischoff.blogspot.com/2010/09/valproato-de-sodio.html' title='Valproato de Sódio'/><author><name>Helga Bischoff</name><uri>http://www.blogger.com/profile/08405263765684348837</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEihKVWoB58uUoLc7y6Qb9tkzXpeTsY_XFfn0-AufGMvESm9uBmZ5fzFANu4dshHkqmWyE9f0TmESGfuDsgaeSD0gOHMMnmm97FLV3i1B5Hl9lTpw7kQvqbn4G4-s6OJlfo/s220/foto+nova.png'/></author><thr:total>1</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6740498378870516287.post-4550215918856463465</id><published>2010-03-25T16:08:00.000-07:00</published><updated>2010-03-25T16:08:38.862-07:00</updated><title type='text'>Tratamento PCA -  Neonatologia</title><content type='html'>&lt;div style=&quot;text-align: justify;&quot;&gt;&lt;i&gt;&lt;b style=&quot;color: red;&quot;&gt;A Persistência do Canal Arterial ocorre quando o canal que separa a circulação do coração para os  pulmões da circulação do coração para o corpo, não se fecha depois do  nascimento. Isso ocorre com frequencia em prematuros e deve ser corrigido o mais rápido possível. O medicamento mais indicado neste caso é a indometacina injetável, pois atuará sobre as prostaglandinas que mantém o canal aberto, provocando seu fechamento. Porém, a indometacina está em falta no mercado internacional, dificultando o tratamento em todos os hospitais. Um substituto para a indometacina é o ibuprofeno injetável, que está sendo usado em muitos hospitais.&amp;nbsp; Estudos revelam que o ibuprofeno possui ação semelhante à indometacina, porém sua eficácia seria menor. Em contrapartida, os efeitos adversos com o uso de ibuprofeno também tornam-se menores em comparação aos da indometacina. Ambos não são produzidos ainda no Brasil, sendo necessária a importação. Em relação a posologia, para tratamento de PCA deve-se fazer um ciclo de 3 doses (intervalo de 24 horas entre as doses), a primeira dose deve ser 10 mg/kg, e as outras duas 5 mg/kg. Caso o canal não se feche, ou reabra, deve-se realizar um segundo ciclo nas mesmas condições. O ideal é que o tratamento farmacológico seja realizado até o 14o. dia de vida, pois após ocorre queda na produção de prostaglandinas. &lt;/b&gt;&lt;/i&gt;&lt;b&gt;&lt;br /&gt;
&lt;/b&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://helgabischoff.blogspot.com/feeds/4550215918856463465/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://helgabischoff.blogspot.com/2010/03/tratamento-pca-neonatologia.html#comment-form' title='9 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/4550215918856463465'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/4550215918856463465'/><link rel='alternate' type='text/html' href='http://helgabischoff.blogspot.com/2010/03/tratamento-pca-neonatologia.html' title='Tratamento PCA -  Neonatologia'/><author><name>Helga Bischoff</name><uri>http://www.blogger.com/profile/08405263765684348837</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEihKVWoB58uUoLc7y6Qb9tkzXpeTsY_XFfn0-AufGMvESm9uBmZ5fzFANu4dshHkqmWyE9f0TmESGfuDsgaeSD0gOHMMnmm97FLV3i1B5Hl9lTpw7kQvqbn4G4-s6OJlfo/s220/foto+nova.png'/></author><thr:total>9</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6740498378870516287.post-1061971488133699675</id><published>2010-03-01T16:29:00.000-08:00</published><updated>2010-03-01T16:29:33.287-08:00</updated><title type='text'>Farmácia Clínica em Pediatria e Neonatologia</title><content type='html'>&lt;div style=&quot;text-align: justify;&quot;&gt;&lt;b&gt;&lt;span style=&quot;color: magenta;&quot;&gt;Trabalhar com pacientes pediátricos e neonatos é um desafio. Um desafio porque a grande maioria dos medicamentos não são adequados para estes pacientes, tanto pela sua forma farmacêutica (cápsulas, comprimidos que não podem ser macerados e/ou partidos) tanto pela falta de estudos que comprovem a sua eficácia e segurança. O farmacêutico tem que estar em constante aprendizado, trocar informações com médicos, enfermeiros, nutricionistas, fisioterapeutas, entre outros profissionais, agregando novos conhecimentos que possam contribuir para melhor acompanhamento farmacoterapêutico do paciente. É importante que o farmacêutico tenha conhecimentos de manipulação de fórmulas, interações medicamentosas, custo do tratamento e saber procurar alternativas de tratamento quando não é viável a alteração da forma farmacêutica. Num segundo momento, o farmacêutico deve conhecer os pais do paciente, realizar anamnese farmacêutica e orientar quanto ao uso correto dos medicamentos para uso em domicílio (a grande maioria dos pais não sabe como fazê-lo da maneira correta). A Farmácia Clínica em Pediatria e Neonatologia é uma área que tem muito a crescer pois ainda estamos engatinhando no mar de possibilidades que podem ser criadas para oferecer o melhor tratamento a estes pacientes.&lt;/span&gt;&lt;/b&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://helgabischoff.blogspot.com/feeds/1061971488133699675/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://helgabischoff.blogspot.com/2010/03/farmacia-clinica-em-pediatria-e.html#comment-form' title='3 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/1061971488133699675'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/1061971488133699675'/><link rel='alternate' type='text/html' href='http://helgabischoff.blogspot.com/2010/03/farmacia-clinica-em-pediatria-e.html' title='Farmácia Clínica em Pediatria e Neonatologia'/><author><name>Helga Bischoff</name><uri>http://www.blogger.com/profile/08405263765684348837</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEihKVWoB58uUoLc7y6Qb9tkzXpeTsY_XFfn0-AufGMvESm9uBmZ5fzFANu4dshHkqmWyE9f0TmESGfuDsgaeSD0gOHMMnmm97FLV3i1B5Hl9lTpw7kQvqbn4G4-s6OJlfo/s220/foto+nova.png'/></author><thr:total>3</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6740498378870516287.post-3141568580119645483</id><published>2010-02-22T16:01:00.000-08:00</published><updated>2010-02-22T16:01:32.365-08:00</updated><title type='text'>Hipodermóclise novamente...</title><content type='html'>&lt;div style=&quot;color: #741b47; font-family: Verdana,sans-serif; text-align: justify;&quot;&gt;&lt;i&gt;A hipodermóclise traz um desafio para os farmacêuticos, onde é necessária muita pesquisa e prática clínica, pois a grande maioria das bulas não traz descrito a possibilidade de administração SC. Não é porque não consta na bula que não é possível. Temos que recorrer a diversos mecanismos de buscas, como Micromedex, Clinical Pharmacology, livros e artigos científicos para depois chegarmos a uma conclusão. Segue dois links de artigos que achei sobre hipodermóclise.&lt;/i&gt;&lt;/div&gt;&lt;br /&gt;
&lt;a href=&quot;http://www.apmcg.pt/files/54/documentos/20070528184147167970.pdf&quot;&gt;http://www.apmcg.pt/files/54/documentos/20070528184147167970.pdf&lt;/a&gt;&lt;br /&gt;
&lt;br /&gt;
&lt;a href=&quot;http://www.coren-sp.gov.br/drupal6/sites/default/files/hipodermoclise_0.pdf&quot;&gt;http://www.coren-sp.gov.br/drupal6/sites/default/files/hipodermoclise_0.pdf&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='http://helgabischoff.blogspot.com/feeds/3141568580119645483/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://helgabischoff.blogspot.com/2010/02/hipodermoclise-novamente.html#comment-form' title='1 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/3141568580119645483'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/3141568580119645483'/><link rel='alternate' type='text/html' href='http://helgabischoff.blogspot.com/2010/02/hipodermoclise-novamente.html' title='Hipodermóclise novamente...'/><author><name>Helga Bischoff</name><uri>http://www.blogger.com/profile/08405263765684348837</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEihKVWoB58uUoLc7y6Qb9tkzXpeTsY_XFfn0-AufGMvESm9uBmZ5fzFANu4dshHkqmWyE9f0TmESGfuDsgaeSD0gOHMMnmm97FLV3i1B5Hl9lTpw7kQvqbn4G4-s6OJlfo/s220/foto+nova.png'/></author><thr:total>1</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6740498378870516287.post-6368995262664723082</id><published>2010-01-07T15:35:00.000-08:00</published><updated>2010-01-07T15:35:57.068-08:00</updated><title type='text'>Hipodermóclise</title><content type='html'>&lt;div style=&quot;text-align: justify;&quot;&gt;&lt;span style=&quot;font-family: &amp;quot;Helvetica Neue&amp;quot;,Arial,Helvetica,sans-serif; font-size: small;&quot;&gt;&lt;span style=&quot;color: #351c75;&quot;&gt;Já ouviu falar em hipordemóclise? É uma técnica muito utilizada para pacientes de cuidados paliativos. O medicamento é administrado por via subcutânea, onde ele forma uma espécie de depósito e é absorvido constantemente, sendo considerada uma técnica pouco invasiva. Já é utilizada com medicamentos como morfina e haloperidol. É uma técnica pouco divulgada, mas que merece sua atenção, visto a facilidade na administração e os benefícios que pode oferecer.&lt;/span&gt;&lt;/span&gt;&lt;br /&gt;
&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://helgabischoff.blogspot.com/feeds/6368995262664723082/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://helgabischoff.blogspot.com/2010/01/hipodermoclise.html#comment-form' title='6 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/6368995262664723082'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/6368995262664723082'/><link rel='alternate' type='text/html' href='http://helgabischoff.blogspot.com/2010/01/hipodermoclise.html' title='Hipodermóclise'/><author><name>Helga Bischoff</name><uri>http://www.blogger.com/profile/08405263765684348837</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEihKVWoB58uUoLc7y6Qb9tkzXpeTsY_XFfn0-AufGMvESm9uBmZ5fzFANu4dshHkqmWyE9f0TmESGfuDsgaeSD0gOHMMnmm97FLV3i1B5Hl9lTpw7kQvqbn4G4-s6OJlfo/s220/foto+nova.png'/></author><thr:total>6</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6740498378870516287.post-8459043977706213865</id><published>2010-01-04T15:12:00.000-08:00</published><updated>2010-01-04T15:12:42.198-08:00</updated><title type='text'>Congressos</title><content type='html'>&lt;div style=&quot;text-align: justify;&quot;&gt;&lt;span style=&quot;font-family: Arial,Helvetica,sans-serif; font-size: small;&quot;&gt;&lt;span style=&quot;color: purple;&quot;&gt;Este ano teremos o XX Congresso Panamericano de Farmácia, que será realizado em Porto Alegre - RS. É uma ótima oportunidade para os farmacêuticos enviarem trabalhos. O envio de trabalhos é até o dia 10 de janeiro. Precisamos escrever mais e divulgar o que estamos fazendo. Eu já estou escrevendo os meus, e você? &lt;/span&gt;&lt;/span&gt;&lt;br /&gt;
&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://helgabischoff.blogspot.com/feeds/8459043977706213865/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://helgabischoff.blogspot.com/2010/01/congressos.html#comment-form' title='1 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/8459043977706213865'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/8459043977706213865'/><link rel='alternate' type='text/html' href='http://helgabischoff.blogspot.com/2010/01/congressos.html' title='Congressos'/><author><name>Helga Bischoff</name><uri>http://www.blogger.com/profile/08405263765684348837</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEihKVWoB58uUoLc7y6Qb9tkzXpeTsY_XFfn0-AufGMvESm9uBmZ5fzFANu4dshHkqmWyE9f0TmESGfuDsgaeSD0gOHMMnmm97FLV3i1B5Hl9lTpw7kQvqbn4G4-s6OJlfo/s220/foto+nova.png'/></author><thr:total>1</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6740498378870516287.post-2899860056477027643</id><published>2009-11-08T12:59:00.000-08:00</published><updated>2009-11-08T12:59:29.791-08:00</updated><title type='text'>Assistência Farmacêutica</title><content type='html'>Agora com a nova legislação para Drogarias, o farmacêutico terá que atuar muito mais na linha de frente com o paciente. Com isso, cresce ainda mais a necessidade do farmacêutico se aperfeiçoar com cursos que envolvam atenção farmacêutica. Muitos farmacêuticos que trabalham em drogarias são recém formados e ainda não contam com a experiência da prática para, por exemplo, analisar uma receita adequadamente. Cada vez mais o farmacêutico irá conquistar seu espaço e reconhecimento pela sociedade, mas para isso deve se preparar.</content><link rel='replies' type='application/atom+xml' href='http://helgabischoff.blogspot.com/feeds/2899860056477027643/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://helgabischoff.blogspot.com/2009/11/assistencia-farmaceutica.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/2899860056477027643'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/2899860056477027643'/><link rel='alternate' type='text/html' href='http://helgabischoff.blogspot.com/2009/11/assistencia-farmaceutica.html' title='Assistência Farmacêutica'/><author><name>Helga Bischoff</name><uri>http://www.blogger.com/profile/08405263765684348837</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEihKVWoB58uUoLc7y6Qb9tkzXpeTsY_XFfn0-AufGMvESm9uBmZ5fzFANu4dshHkqmWyE9f0TmESGfuDsgaeSD0gOHMMnmm97FLV3i1B5Hl9lTpw7kQvqbn4G4-s6OJlfo/s220/foto+nova.png'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6740498378870516287.post-5106544704785046197</id><published>2009-09-20T17:03:00.000-07:00</published><updated>2009-09-20T17:03:10.965-07:00</updated><title type='text'>Anamnese Farmacêutica</title><content type='html'>&lt;div style=&quot;text-align: justify;&quot;&gt;&lt;b&gt;&lt;span style=&quot;color: purple;&quot;&gt;A anamnese farmacêutica é importante para que o farmacêutico conheça melhor o paciente, independente se o paciente estiver internado em hospital ou&amp;nbsp; não. Com uma boa anamnese é possível descobrir por exemplo se o paciente é aderente ou não ao tratamento. Segue um modelo que elaborei de anamnese farmacêutica:&lt;/span&gt;&lt;/b&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div class=&quot;separator&quot; style=&quot;clear: both; text-align: center;&quot;&gt;&lt;a href=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEg9rw3uVp3crCscAGdqq9FRneputviysajEmWDTjMKu7VsRCX0aHg5uL6FMfKkYJ22Jx4Spddp2RBRoIOwIz1n2yWJQtKnLf69YreCdCvSazefiWCFq0_oMMfwlbh0jB6SSGwj9IZdMtuzP/s1600-h/ANAMNESE.jpg&quot; imageanchor=&quot;1&quot; style=&quot;margin-left: 1em; margin-right: 1em;&quot;&gt;&lt;img border=&quot;0&quot; height=&quot;320&quot; src=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEg9rw3uVp3crCscAGdqq9FRneputviysajEmWDTjMKu7VsRCX0aHg5uL6FMfKkYJ22Jx4Spddp2RBRoIOwIz1n2yWJQtKnLf69YreCdCvSazefiWCFq0_oMMfwlbh0jB6SSGwj9IZdMtuzP/s320/ANAMNESE.jpg&quot; width=&quot;236&quot; /&gt;&lt;/a&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style=&quot;text-align: justify;&quot;&gt;&lt;br /&gt;
&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://helgabischoff.blogspot.com/feeds/5106544704785046197/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://helgabischoff.blogspot.com/2009/09/anamnese-farmaceutica.html#comment-form' title='1 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/5106544704785046197'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/5106544704785046197'/><link rel='alternate' type='text/html' href='http://helgabischoff.blogspot.com/2009/09/anamnese-farmaceutica.html' title='Anamnese Farmacêutica'/><author><name>Helga Bischoff</name><uri>http://www.blogger.com/profile/08405263765684348837</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEihKVWoB58uUoLc7y6Qb9tkzXpeTsY_XFfn0-AufGMvESm9uBmZ5fzFANu4dshHkqmWyE9f0TmESGfuDsgaeSD0gOHMMnmm97FLV3i1B5Hl9lTpw7kQvqbn4G4-s6OJlfo/s220/foto+nova.png'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEg9rw3uVp3crCscAGdqq9FRneputviysajEmWDTjMKu7VsRCX0aHg5uL6FMfKkYJ22Jx4Spddp2RBRoIOwIz1n2yWJQtKnLf69YreCdCvSazefiWCFq0_oMMfwlbh0jB6SSGwj9IZdMtuzP/s72-c/ANAMNESE.jpg" height="72" width="72"/><thr:total>1</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6740498378870516287.post-838859286865421172</id><published>2009-09-17T16:45:00.000-07:00</published><updated>2009-09-17T16:45:49.117-07:00</updated><title type='text'>Interações medicamentosas</title><content type='html'>&lt;div style=&quot;color: red; text-align: justify;&quot;&gt;&lt;b&gt;Dicas de onde pesquisar interações medicamentosas:&lt;/b&gt;&lt;/div&gt;&lt;ul style=&quot;color: blue; text-align: justify;&quot;&gt;&lt;li&gt;Clinical Pharmacology&lt;/li&gt;
&lt;li&gt;Micromedex&lt;/li&gt;
&lt;li&gt;Epocrates&lt;/li&gt;
&lt;/ul&gt;&lt;b style=&quot;color: red;&quot;&gt;Eu gosto muito do Clinical Pharmacology e do Micromedex. O Clinical é um pouco mais rápido na busca do que o Micromedex, mas se você não estiver com pressa vale a pena pesquisar nos dois para poder comparar informações.&lt;/b&gt;&lt;br style=&quot;color: #c27ba0;&quot; /&gt;</content><link rel='replies' type='application/atom+xml' href='http://helgabischoff.blogspot.com/feeds/838859286865421172/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://helgabischoff.blogspot.com/2009/09/interacoes-medicamentosas.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/838859286865421172'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/838859286865421172'/><link rel='alternate' type='text/html' href='http://helgabischoff.blogspot.com/2009/09/interacoes-medicamentosas.html' title='Interações medicamentosas'/><author><name>Helga Bischoff</name><uri>http://www.blogger.com/profile/08405263765684348837</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEihKVWoB58uUoLc7y6Qb9tkzXpeTsY_XFfn0-AufGMvESm9uBmZ5fzFANu4dshHkqmWyE9f0TmESGfuDsgaeSD0gOHMMnmm97FLV3i1B5Hl9lTpw7kQvqbn4G4-s6OJlfo/s220/foto+nova.png'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6740498378870516287.post-7901915920895129952</id><published>2009-09-15T17:44:00.000-07:00</published><updated>2009-09-15T17:44:05.919-07:00</updated><title type='text'>Glutamina</title><content type='html'>&lt;div style=&quot;text-align: justify;&quot;&gt;&lt;span style=&quot;color: purple;&quot;&gt;&lt;strong&gt;&lt;em&gt;Muitos estudos mostram que a adição de glutamina na nutrição parenteral (NP)&amp;nbsp;só traz benefícios para portadores de Síndrome do Intestino Curto (SIC).&amp;nbsp;Para crianças e neonatos os estudos revelam ainda que além de estimular as vilosidades intestinais e produzir mais vilosidades, a glutamina ajuda na aceitação da dieta enteral e posteriormente da dieta VO. Contudo, observa-se ainda que muitos médicos desconhecem seus efeitos e acabam não&amp;nbsp;incluindo a gluamina&amp;nbsp;na nutrição parenteral, nesta hora torna-se importante a presença do farmacêutico clínico com conhecimentos em NP, garantindo sempre a melhor terapia para cada paciente.&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://helgabischoff.blogspot.com/feeds/7901915920895129952/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://helgabischoff.blogspot.com/2009/09/glutamina.html#comment-form' title='1 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/7901915920895129952'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/7901915920895129952'/><link rel='alternate' type='text/html' href='http://helgabischoff.blogspot.com/2009/09/glutamina.html' title='Glutamina'/><author><name>Helga Bischoff</name><uri>http://www.blogger.com/profile/08405263765684348837</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEihKVWoB58uUoLc7y6Qb9tkzXpeTsY_XFfn0-AufGMvESm9uBmZ5fzFANu4dshHkqmWyE9f0TmESGfuDsgaeSD0gOHMMnmm97FLV3i1B5Hl9lTpw7kQvqbn4G4-s6OJlfo/s220/foto+nova.png'/></author><thr:total>1</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6740498378870516287.post-5571706586584393699</id><published>2009-09-13T17:21:00.000-07:00</published><updated>2009-09-13T17:21:52.703-07:00</updated><title type='text'>Cuidados Paliativos em ICC</title><content type='html'>Muito se fala em cuidados paliativos para pacientes com câncer, porém pouco se fala para pacientes com insuficiência cardíaca. Passo um link &lt;a href=&quot;http://bases.bireme.br/cgi-bin/wxislind.exe/iah/online/?IsisScript=iah/iah.xis&amp;amp;src=google&amp;amp;base=LILACS&amp;amp;lang=p&amp;amp;nextAction=lnk&amp;amp;exprSearch=508141&amp;amp;indexSearch=ID&quot;&gt;Cuidados paliativos na insuficiência cardíaca&lt;/a&gt;&amp;nbsp;Neste link tem um artigo que escrevi em conjunto com alguns colegas farmacêuticos, onde buscamos informações na literatura a respeito deste assunto.</content><link rel='replies' type='application/atom+xml' href='http://helgabischoff.blogspot.com/feeds/5571706586584393699/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://helgabischoff.blogspot.com/2009/09/cuidados-paliativos-em-icc.html#comment-form' title='0 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/5571706586584393699'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/5571706586584393699'/><link rel='alternate' type='text/html' href='http://helgabischoff.blogspot.com/2009/09/cuidados-paliativos-em-icc.html' title='Cuidados Paliativos em ICC'/><author><name>Helga Bischoff</name><uri>http://www.blogger.com/profile/08405263765684348837</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEihKVWoB58uUoLc7y6Qb9tkzXpeTsY_XFfn0-AufGMvESm9uBmZ5fzFANu4dshHkqmWyE9f0TmESGfuDsgaeSD0gOHMMnmm97FLV3i1B5Hl9lTpw7kQvqbn4G4-s6OJlfo/s220/foto+nova.png'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6740498378870516287.post-1070272033514753472</id><published>2009-08-25T18:21:00.000-07:00</published><updated>2009-08-25T18:21:36.100-07:00</updated><title type='text'></title><content type='html'>&lt;span style=&quot;color: red;&quot;&gt;&lt;strong&gt;Farmacêutico clínico, uma necessidade de mercado&lt;/strong&gt;&lt;/span&gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;div style=&quot;text-align: justify;&quot;&gt;Hoje, muitos hospitais estão em busca de certificações de qualidade, que por sua vez são fornecidas somente aos hospitais que atingem os objetivos propostos e garantem assim, segurança total em seus procedimentos. Dentre as diversas certificações de qualidade existentes, a maioria exige a presença de profissionais farmacêuticos atuando diretamente com o corpo clínico e com o paciente. Esta atuação deve ser constante e deve estar registrada em documentos que validem o processo. O farmacêutico deve estar capacitado para intervir junto à equipe médica em vários momentos, principalmente na prescrição dos medicamentos de cada paciente. Cada vez mais, o mercado está exigindo profissionais farmacêuticos especialistas em farmácia clínica. Podemos dizer que praticamente nenhuma faculdade de farmácia contempla uma grade curricular adequada para formar farmacêuticos clínicos na graduação, levando os profissionais a adquirirem esta formação através de cursos de pós-graduação e estágios na área. Algumas atividades devem ser exclusivamente desempenhadas pelos farmacêuticos clínicos, porém devido à falta no mercado deste tipo de profissional, muitas vezes estas atividades acabam sendo realizadas por farmacêuticos que não tem o conhecimento adequado, e outras vezes, sequer são realizadas. Porém, vale lembrar que o farmacêutico clínico precisa se aprofundar em áreas específicas, através da prática e de cursos. Este conhecimento específico é um diferencial e torna-se importante, por exemplo, para tratar determinado grupo de pacientes. Muitos hospitais estão aderindo à Campanha 5 Milhões de Vidas, através de protocolos que gerenciam risco e segurança do paciente hospitalizado, dentre estes protocolos vale destacar um exemplo da importância da participação do farmacêutico clínico especializado em cardiologia: Prevenir Danos por Medicações de Alto Risco - foco em anticoagulantes. Esta campanha tem o objetivo de diminuir um terço dos eventos adversos causados em hospitalizações e pode ser mensurado pela queda da mortalidade hospitalar. Num futuro próximo, o mercado exigirá não só farmacêuticos clínicos, mas também farmacêuticos clínicos especialistas em determinadas áreas, garantindo maior segurança ao paciente. Cabe a nós farmacêuticos, nos preparar para atender a esta necessidade.&lt;/div&gt;&lt;div style=&quot;text-align: right;&quot;&gt;&lt;em&gt;Helga Bischoff&lt;/em&gt;&lt;/div&gt;&lt;div style=&quot;text-align: right;&quot;&gt;&lt;span style=&quot;font-size: x-small;&quot;&gt;Texto publicado no Suplemento da Revista Socesp Volume 19- Edição 2 Abril/ Maio/Junho 2009.&lt;br /&gt;
&lt;/span&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://helgabischoff.blogspot.com/feeds/1070272033514753472/comments/default' title='Postar comentários'/><link rel='replies' type='text/html' href='http://helgabischoff.blogspot.com/2009/08/farmaceutico-clinico-uma-necessidade-de.html#comment-form' title='1 Comentários'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/1070272033514753472'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6740498378870516287/posts/default/1070272033514753472'/><link rel='alternate' type='text/html' href='http://helgabischoff.blogspot.com/2009/08/farmaceutico-clinico-uma-necessidade-de.html' title=''/><author><name>Helga Bischoff</name><uri>http://www.blogger.com/profile/08405263765684348837</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='21' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEihKVWoB58uUoLc7y6Qb9tkzXpeTsY_XFfn0-AufGMvESm9uBmZ5fzFANu4dshHkqmWyE9f0TmESGfuDsgaeSD0gOHMMnmm97FLV3i1B5Hl9lTpw7kQvqbn4G4-s6OJlfo/s220/foto+nova.png'/></author><thr:total>1</thr:total></entry></feed>